Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07490964Not Yet Recruiting

Polycystic Ovary Syndrome in Type 1 Diabetes

Role: collaborator

NCT04979377Completed

Prevalence of Hyperandrogenism in Type 1 Diabetes

Role: collaborator

NCT02542735Completed

Incidence of Type 2 Diabetes in the di@Bet.es Study

Role: collaborator

NCT01337141Not ApplicableCompleted

A Telematic Program for Optimization of Metabolic Control in Diabetes Mellitus Type 1 (DM1) Patients

Role: lead

NCT02294526Not ApplicableCompleted

A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients

Role: lead

NCT02153879Phase 4Completed

Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment

Role: collaborator

All 6 trials loaded